Caspase-3 in the central nervous system: Beyond apoptosis

Trends in Neurosciences

Volumn 35, Issue 11, 2012, Pages 700-709

  D'Amelio, Marcello ^a,b   Sheng, Morgan ^c   Cecconi, Francesco ^a,d  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Alzheimer's disease; Long term depression; Long term potentiation; Neuronal differentiation; Synaptic loss; Synaptic plasticity

Indexed keywords

CASPASE 3;

ALZHEIMER DISEASE; APOPTOSIS; DEGENERATIVE DISEASE; HUNTINGTON CHOREA; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NEURAL TUBE; NEURITE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 3; CASPASE INHIBITORS; DISEASE MODELS, ANIMAL; EMBRYONIC DEVELOPMENT; ENZYME ACTIVATION; HUMANS; HUNTINGTON DISEASE; LONG-TERM SYNAPTIC DEPRESSION; MICE; MICE, KNOCKOUT; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; NERVE NET; NERVE TISSUE PROTEINS; NERVOUS SYSTEM; NEURAL TUBE; NEURONS; PARKINSON DISEASE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84867903332     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2012.06.004     Document Type: Review

References (113)

1. Yuan J., et al. Apoptosis in the nervous system. Nature 2000, 407:802-809.
2. Haydar T.F., et al. The role of cell death in regulating the size and shape of the mammalian forebrain. Cereb. Cortex 1999, 9:621-626.
3. Kuida K., et al. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 1996, 384:368-372.
4. Rotonda J., et al. The three-dimensional structure of apopain/CPP32, a key mediator of apoptosis. Nat. Struct. Biol. 1996, 3:619-625.
5. Strappazzon F., et al. Non-apoptotic roles for death-related molecules: When mitochondria chose cell fate. Exp. Cell Res. 2012, 318:1309-1315.
6. Schulze-Osthoff K., et al. Apoptosis signaling by death receptors. Eur. J. Biochem. 1998, 254:439-459.
7. Green D.R., et al. The pathophysiology of mitochondrial cell death. Science 2004, 305:626-629.
8. Er E., et al. Mitochondria as the target of the pro-apoptotic protein Bax. Biochim. Biophys. Acta 2006, 1757:1301-1311.
9. Kroemer G., et al. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 2007, 87:99-163.
10. Labi V., et al. BH3-only proteins in cell death initiation, malignant disease and anticancer therapy. Cell Death Differ. 2006, 13:1325-1338.
11. Hofmann K., Bucher P. The CARD domain: a new apoptotic signalling motif. Trends Biochem. Sci. 1997, 22:155-156.
12. Cain K., et al. Apaf-1 oligomerizes into biologically active approximately 700-kDa and inactive approximately 1.4-MDa apoptosome complexes. J. Biol. Chem. 2000, 275:6067-6070.
13. Taylor R.C., et al. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 2008, 9:231-241.
14. Golks A., et al. c-FLIPR, a new regulator of death receptor-induced apoptosis. J. Biol. Chem. 2005, 280:14507-14513.
15. Thome M., et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997, 386:517-521.
16. Neumar R.W., et al. Cross-talk between calpain and caspase proteolytic systems during neuronal apoptosis. J. Biol. Chem. 2003, 278:14162-14167.
17. Riedl S.J. Structural basis for the inhibition of caspase-3 by XIAP. Cell 2001, 104:791-800.
18. Choi Y.E., et al. The E3 ubiquitin ligase cIAP1 binds and ubiquitinates caspase-3 and -7 via unique mechanisms at distinct steps in their processing. J. Biol. Chem. 2009, 284:12772-12782.
19. Silke J., et al. The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sites. J. Cell Biol. 2002, 157:115-124.
20. Schile A.J., et al. Regulation of apoptosis by XIAP ubiquitin-ligase activity. Genes Dev. 2008, 22:2256-2266.
21. Mazarakis N.D., et al. Apoptosis in neural development and disease. Arch. Dis. Child. 1997, 77:165-170.
22. Jacobson M.D., et al. Programmed cell death in animal development. Cell 1997, 88:347-354.
23. Madden S.D., Cotter T.G. Cell death in brain development and degeneration: control of caspase expression may be key!. Mol. Neurobiol. 2008, 37:1-6.
24. Buss R.R., et al. Adaptive roles of programmed cell death during nervous system development. Annu. Rev. Neurosci. 2006, 29:1-35.
25. Blaschke A.J., et al. Widespread programmed cell death in proliferative and postmitotic regions of the fetal cerebral cortex. Development 1996, 122:1165-1174.
26. Daish T.J., et al. Drosophila caspase DRONC is required for specific developmental cell death pathways and stress induced apoptosis. Dev. Cell 2004, 7:909-915.
27. Xu D., et al. The CARD-carrying caspase Dronc is essential for most, but not all, developmental cell death in Drosophila. Development 2005, 132:2125-2134.
28. Waldhuber M., et al. The Drosophila caspase DRONC is required for metamorphosis and cell death in response to irradiation and developmental signals. Mech. Dev. 2005, 122:914-927.
29. Perez-Garijo A., et al. Caspase inhibition during apoptosis causes abnormal signalling and developmental aberrations in Drosophila. Development 2004, 131:5591-5598.
30. Zhou L., et al. HAC-1, a Drosophila homolog of APAF-1 and CED-4 functions in developmental and radiation-induced apoptosis. Mol. Cell 1999, 4:745-755.
31. Kanuka H., et al. Control of the cell death pathway by Dapaf-1, a Drosophila Apaf-1/CED-4-related caspase activator. Mol. Cell 1999, 4:757-769.
32. Leonard J.R., et al. Strain-dependent neurodevelopmental abnormalities in caspase-3-deficient mice. J. Neuropathol. Exp. Neurol. 2002, 61:673-677.
33. Kuida K., et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998, 94:325-337.
34. Cecconi F., et al. Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development. Cell 1998, 94:727-737.
35. Yeo W., Gautier J. Early neural cell death: dying to become neurons. Dev. Biol. 2004, 274:233-244.
36. Jankowski J., et al. Physiological Purkinje cell death is spatiotemporally organized in the developing mouse cerebellum. Cerebellum 2009, 8:277-290.
37. Oppenheim R.W., et al. Programmed cell death of developing mammalian neurons after genetic deletion of caspases. J. Neurosci. 2001, 21:4752-4760.
38. White F.A., et al. Widespread elimination of naturally occurring neuronal death in Bax-deficient mice. J. Neurosci. 1998, 18:1428-1439.
39. Jung A.R., et al. Misplacement of Purkinje cells during postnatal development in Bax knock-out mice: a novel role for programmed cell death in the nervous system?. J. Neurosci. 2008, 28:2941-2948.
40. Fernando P., et al. Neural stem cell differentiation is dependent upon endogenous caspase 3 activity. FASEB J. 2005, 19:1671-1673.
41. Fernando P., et al. Caspase-3 activity is required for skeletal muscle differentiation. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:11025-11030.
42. Okuyama R., et al. High commitment of embryonic keratinocytes to terminal differentiation through a Notch1-caspase-3 regulatory mechanism. Dev. Cell 2004, 6:551-562.
43. Campbell D.S., et al. Apoptotic pathway and MAPKs differentially regulate chemotropic responses of retinal growth cones. Neuron 2003, 37:939-952.
44. Fujita J., et al. Caspase activity mediates the differentiation of embryonic stem cells. Cell Stem Cell 2008, 2:595-601.
45. Fazzio T.G., Panning B. Control of embryonic stem cell identity by nucleosome remodeling enzymes. Curr. Opin. Genet. Dev. 2010, 20:500-504.
46. Huesmann G.R., Clayton D.F. Dynamic role of postsynaptic caspase-3 and BIRC4 in zebra finch song-response habituation. Neuron 2006, 52:1061-1072.
47. Kaplan Y., et al. Gradients of a ubiquitin E3 ligase inhibitor and a caspase inhibitor determine differentiation or death in spermatids. Dev. Cell 2010, 19:160-173.
48. Ohsawa S., et al. Maturation of the olfactory sensory neurons by Apaf-1/caspase-9-mediated caspase activity. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:13366-13371.
49. Pasterkamp R.J., et al. Semaphorin 7A promotes axon outgrowth through integrins and MAPKs. Nature 2003, 424:398-405.
50. Shepherd J.D., Huganir R.L. The cell biology of synaptic plasticity: AMPA receptor trafficking. Annu. Rev. Cell Dev. Biol. 2007, 23:613-643.
51. Zhou Q., et al. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron 2004, 44:749-757.
52. Li Z., et al. Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. Cell 2010, 141:859-871.
53. Jiao S., Li Z. Nonapoptotic function of BAD and BAX in long-term depression of synaptic transmission. Neuron 2011, 70:758-772.
54. Gilman C.P., Mattson M.P. Do apoptotic mechanisms regulate synaptic plasticity and growth-cone motility?. Neuromol. Med. 2002, 2:197-214.
55. Kuo C.T., et al. Identification of E2/E3 ubiquitinating enzymes and caspase activity regulating Drosophila sensory neuron dendrite pruning. Neuron 2006, 51:283-290.
56. Stepanichev M.Y., et al. Central administration of a caspase inhibitor impairs shuttle-box performance in rats. Neuroscience 2005, 136:579-591.
57. Higgins G.C., et al. Oxidative stress: emerging mitochondrial and cellular themes and variations in neuronal injury. J. Alzheimers Dis. 2010, 20(Suppl. 2):S453-S473.
58. Galluzzi L., et al. Mitochondrial membrane permeabilization in neuronal injury. Nat. Rev. Neurosci. 2009, 10:481-494.
59. Naoi M., et al. Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival. J. Neural Transm. 2009, 116:1371-1381.
60. Abou-Sleiman P.M., et al. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 2006, 7:207-219.
61. Mandemakers W., et al. A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases. J. Cell Sci. 2007, 120:1707-1716.
62. Milnerwood A.J., et al. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci. 2010, 33:513-523.
63. Troy C.M., et al. Regulation of caspases in the nervous system: implications for functions in health and disease. Prog. Mol. Biol. Transl. Sci. 2011, 299:265-305.
64. Ribe E.M., et al. Mechanisms of neuronal death in disease: defining the models and the players. Biochem. J. 2008, 415:165-182.
65. Ekshyyan O., Aw T.Y. Apoptosis in acute and chronic neurological disorders. Front. Biosci. 2004, 9:1567-1576.
66. Friedlander R.M. Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med. 2003, 348:1365-1375.
67. Smale G., et al. Evidence for apoptotic cell death in Alzheimer's disease. Exp. Neurol. 1995, 133:225-230.
68. Dragunow M., et al. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport 1995, 6:1053-1057.
69. Thomas L.B., et al. DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Exp. Neurol. 1995, 133:265-272.
70. Colurso G.J., et al. Quantitative assessment of DNA fragmentation and beta-amyloid deposition in insular cortex and midfrontal gyrus from patients with Alzheimer's disease. Life Sci. 2003, 73:1795-1803.
71. Cavallucci V., D'Amelio M. Matter of life and death: the pharmacological approaches targeting apoptosis in brain diseases. Curr. Pharm. Des. 2011, 17:215-229.
72. Sureda F.X., et al. Antiapoptotic drugs: a therapeutic strategy for the prevention of neurodegenerative diseases. Curr. Pharm. Des. 2011, 17:230-234.
73. Viana R.J., et al. Organelle stress sensors and cell death mechanisms in neurodegenerative diseases. CNS Neurol. Disord. Drug Targets 2010, 9:679-692.
74. Fuchs Y., Steller H. Programmed cell death in animal development and disease. Cell 2011, 147:742-758.
75. Lee S.J., et al. Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci. Res. 2011, 70:339-348.
76. Goldberg Y.P., et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat. Genet. 1996, 13:442-449.
77. Wellington C.L., et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 1998, 273:9158-9167.
78. Wellington C.L., Hayden M.R. Of molecular interactions, mice and mechanisms: new insights into Huntington's disease. Curr. Opin. Neurol. 1997, 10:291-298.
79. Wellington C.L., et al. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J. Biol. Chem. 2000, 275:19831-19838.
80. O'Brien R.J., Wong P.C. Amyloid precursor protein processing and Alzheimer's disease. Annu. Rev. Neurosci. 2011, 34:185-204.
81. Gervais F.G., et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-β precursor protein and amyloidogenic Aβ peptide formation. Cell 1999, 97:395-406.
82. Borg J.P., et al. The X11a protein slows cellular amyloid precursor protein processing and reduces Aβ40 and Aβ42 secretion. J. Biol. Chem. 1998, 273:14761-14766.
83. Dumanchin-Njock C., et al. The caspase-derived C-terminal fragment of betaAPP induces caspase-independent toxicity and triggers selective increase of Abeta42 in mammalian cells. J. Neurochem. 2001, 8:1153-1161.
84. Kim T.W., et al. Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science 1997, 277:373-376.
85. Loetscher H., et al. Presenilins are processed by caspase-type proteases. J. Biol. Chem. 1997, 272:20655-20659.
86. 2+ homeostasis and accelerates apoptosis. J. Biol. Chem. 2006, 281:16649-16655.
87. Alves da Costa C., et al. The C-terminal fragment of presenilin 2 triggers p53-mediated staurosporine-induced apoptosis, a function independent of the presenilinase-derived N-terminal counterpart. J. Biol. Chem. 2003, 278:12064-12069.
88. Vito P., et al. Generation of anti-apoptotic presenilin-2 polypeptides by alternative transcription, proteolysis, and caspase-3 cleavage. J. Biol. Chem. 1997, 272:28315-28320.
89. Vito P., et al. Requirement of the familial Alzheimer's disease PS2 for apoptosis: opposing effect of ALG-3. J. Biol. Chem. 1996, 271:31025-31028.
90. Walter J., et al. Proteolytic fragments of the Alzheimer's disease associated presenilins-1 and -2 are phosphorylated in TiTo by distinct cellular mechanisms. Biochemistry 1998, 37:5961-5967.
91. Walter J., et al. Phosphorylation of presenilin-2 regulates its cleavage by caspases and retard progression of apoptosis. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:1391-1396.
92. Tesco G., et al. Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron 2007, 54:721-737.
93. Rohn T.T. Caspase-cleaved TAR DNA-binding protein-43 is a major pathological finding in Alzheimer's disease. Brain Res. 2009, 1228:189-198.
94. de Calignon A., et al. Caspase activation precedes and leads to tangles. Nature 2010, 464:1201-1214.
95. Scheff S.W., et al. Synaptic alterations in CA1 in mild Alzheimer's disease and mild cognitive impairment. Neurology 2007, 68:1501-1508.
96. D'Amelio M., et al. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat. Neurosci. 2011, 14:69-76.
97. 1-42 inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β. Nat. Neurosci. 2011, 14:545-547.
98. Bradley C.A., et al. A pivotal role of GSK-3 in synaptic plasticity. Front. Mol. Neurosci. 2012, 5:13.
99. Hernández F., et al. GSK3: a possible link between beta amyloid peptide and tau protein. Exp. Neurol. 2010, 223:322-325.
100. Louneva N., et al. Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease. Am. J. Pathol. 2008, 173:1488-1495.
101. Sultana R., et al. Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer's disease. J. Neurosci. Res. 2010, 88:469-477.
102. Mochizuki H., et al. Histochemical detection of apoptosis in Parkinson's disease. J. Neurol. Sci. 1996, 137:120-123.
103. Alves da Costa C., Checler F. Apoptosis in Parkinson's disease: is p53 the missing link between genetic and sporadic Parkinsonism?. Cell. Signal. 2011, 23:963-968.
104. Burke R.E. Programmed cell death in Parkinson's disease. Handb. Clin. Neurol. 2007, 83:591-605.
105. Giaime E., et al. Caspase-3-derived C-terminal product of synphilin-1 displays antiapoptotic function via modulation of the p53-dependent cell death pathway. J. Biol. Chem. 2006, 281:11515-11522.
106. Engelender S., et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 1999, 22:110-114.
107. Burguillos M.A., et al. Caspase signalling controls microglia activation and neurotoxicity. Nature 2011, 472:319-324.
108. Garrido C., Kroemer G. Life's smile, death's grin: vital functions of apoptosis-executing proteins. Curr. Opin. Cell Biol. 2004, 16:639-646.
109. Wang W.L., et al. Lens fiber cell differentiation and denucleation are disrupted through expression of the N-terminal nuclear receptor box of NCOA6 and result in p53-dependent and p53-independent apoptosis. Mol. Biol. Cell 2010, 21:2453-2468.
110. Gabet A.S., et al. Caspase-activated ROCK-1 allows erythroblast terminal maturation independently of cytokine-induced Rho signaling. Cell Death Differ. 2011, 18:678-6789.
111. Arama E., et al. Caspase activity and a specific cytochrome c are required for sperm differentiation in Drosophila. Dev. Cell 2003, 4:687-697.
112. Zermati Y., et al. Nonapoptotic role for Apaf-1 in the DNA damage checkpoint. Mol. Cell 2007, 28:624-637.
113. Ferraro E., et al. Apaf1 plays a pro-survival role by regulating centrosome morphology and function. J. Cell Sci. 2011, 124:3450-3463.